Back to Agenda
The Changing Landscape for Bioinnovation: The Emergence of Small Pharma, Strategic Alliances, and Precision Medicine (Part 2 of 2)
Session Chair(s)
Kenneth I. Kaitin, PHD
Professor and Senior Fellow, Tufts Center for the Study of Drug Development, United States
The landscape for pharmaceutical R&D is shifting dramatically: from large pharmaceutical companies to small and specialty pharmaceutical companies, from vertically integrated companies to collaborative partnerships and innovation networks, and from high volume markets to targeted and precision medicines. This two-part forum will explore the impact of these changes on the R&D landscape.
This second forum will examine the ramifications of industry’s shift to targeted and precision medicines, and the impact smaller patient populations and smaller market opportunities are having on portfolio and R&D investment decisions.
Part 1 will take place on Tuesday at 8:00 AM (Session #225).
Learning Objective : Identify shifts in pharmaceutical R&D; Discuss the impact of these changes on the R&D landscape; Examine the ramifications of industry's shift to targeted and precision medicines in the discovery, development, and commercialization of new medical products.
Speaker(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development, Tufts University School of Medicine, United States
Panelist
Scott M. Whitcup, MD
Chief Scientific Officer, Allergan, Inc., United States
Panelist
Alberto Grignolo, PHD
Editor-in-Chief, DIA Global Forum, United States
Panelist
Michael James Doherty
Head of Product Development, Foundation Medicine, United States
Panelist
Have an account?